We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

88 hedge funds and large institutions have $97.1M invested in CytomX Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 19 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,430% more call options, than puts

Call options by funds: $353K | Put options by funds: $10K

250% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 8

91% more capital invested

Capital invested by funds: $50.7M → $97.1M (+$46.4M)

29% more funds holding

Funds holding: 68 → 88 (+20)

16.94% more ownership

Funds ownership: 48.85% → 65.79% (+17%)

21% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 24

Holders
88
Holders Change
+20
Holders Change %
+29.41%
% of All Funds
1.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
19
Reduced
24
Closed
8
Calls
$353K
Puts
$10K
Net Calls
+$343K
Net Calls Change
+$314K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$6.54M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.69M
3
SCM
Sio Capital Management
New York
+$2.95M
4
SSA
Schonfeld Strategic Advisors
New York
+$2.35M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.66M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$706K
2
LCM
Laurion Capital Management
New York
-$609K
3
Marshall Wace
Marshall Wace
United Kingdom
-$574K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$483K
5
Citadel Advisors
Citadel Advisors
Florida
-$400K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$583K – – –
Two Sigma Investments
27
Two Sigma Investments
New York
$553K +$442K +239,632 +1,695%
BC
28
BIT Capital
Germany
$547K +$463K +250,910 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$528K -$45.9K -24,855 -9%
CPC
30
Congress Park Capital
New York
$510K -$10.2K -5,500 -2%
Squarepoint
31
Squarepoint
New York
$458K +$110K +59,618 +40%
CC
32
Clearline Capital
New York
$429K – – –
Man Group
33
Man Group
United Kingdom
$417K +$353K +191,060 New
Jane Street
34
Jane Street
New York
$401K +$285K +154,509 +528%
Fidelity Investments
35
Fidelity Investments
Massachusetts
$399K -$706K -382,247 -68%
ACM
36
ADAR1 Capital Management
Texas
$338K +$286K +155,000 New
GCP
37
GSA Capital Partners
United Kingdom
$324K +$82K +44,405 +43%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$320K +$195K +105,600 +256%
Northern Trust
39
Northern Trust
Illinois
$292K -$2.19K -1,184 -0.9%
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
$290K +$245K +132,940 +51,328%
Citigroup
41
Citigroup
New York
$270K +$228K +123,653 New
Bank of Montreal
42
Bank of Montreal
Ontario, Canada
$238K +$67.2K +36,400 +51%
LPL Financial
43
LPL Financial
California
$201K -$33.1K -17,950 -16%
PAS
44
Point72 Asia (Singapore)
Singapore
$190K +$161K +87,226 New
Walleye Capital
45
Walleye Capital
New York
$187K +$158K +85,638 New
CIC
46
Cornercap Investment Counsel
Georgia
$177K – – –
Bank of America
47
Bank of America
North Carolina
$170K +$111K +60,035 +338%
PAG
48
Private Advisor Group
New Jersey
$151K -$7.38K -4,000 -5%
SFI
49
Susquehanna Fundamental Investments
Pennsylvania
$124K +$105K +56,745 New
YIH
50
Y-Intercept (HK)
Hong Kong
$121K +$103K +55,595 New
1
2
3 4

CTMX Hedge Fund Activity: Q1 2024 in Review

88 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2024, worth a combined $97.1M — up 91% from $50.7M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new CTMX positions and 8 closed out — a net gain of 20 holders — while 19 added to existing stakes and 24 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $6.54M. The largest seller was Fidelity Investments, cutting an estimated $706K.

  • 88 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2024, up from 68 in Q4 2023.
  • Funds reported $97.1M of CytomX Therapeutics stock for Q1 2024, up 91% quarter-over-quarter.
  • 28 funds opened new CytomX Therapeutics positions in Q1 2024 and 8 closed out, a net change of +20 holders.
  • The largest CytomX Therapeutics buyer in Q1 2024 was OrbiMed, an estimated $6.54M added.
  • The largest CytomX Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $706K sold.

Based on aggregated 13F filings for Q1 2024.